Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific Corporation

http://www.bostonscientific.com

Latest From Boston Scientific Corporation

News We're Watching: Tricuspid Procedure Boom, Boston Scientific Borrows $2Bn, And More

Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, GE Healthcare and Biofourmis announced a deal to collaborate on virtual care; Cleerly touts a new CPT code for its Ischemia cardiac diagnostic software; Boston Scientific announced how it plans to pay for Axonics; a Wells Fargo survey suggests the market for transcatheter tricuspid valve repair and replacement will grow faster than previously imagined; Virtual Incision earns FDA de novo authorization for its MIRA miniaturized surgical system for colectomy procedures; and MMI and Fabric announce major financing rounds.

News We're Watching Approvals

Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance

Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.

Drug Approval Standards Clinical Trials

Orphan Drug, Domestic Developers Shine In China Annual Approvals Tally

10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.

China Approvals

Bausch + Lomb Dry Eye Franchise Ahead Of Growth Targets

Having acquired Xiidra from Novartis and getting US approval of Miebo in 2023, B+L’s two-product dry eye franchise delivered 66% year-over-year growth during Q4 2023.

Sales & Earnings Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Monitoring Equipment & Devices
    • Radiofrequency Devices
    • Rehabilitation Equipment and Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
  • Other Names / Subsidiaries
    • Apama Medical
    • Asthmatx
    • Atritech, Inc.
    • Augmenix, Inc.
    • Biocompatibles International plc
    • BridgePoint Medical, Inc.
    • BTG plc
    • BTG Specialty Pharmaceuticals
    • Cameron Health, Inc.
    • Cardiovascular Imaging Systems, Inc.
    • CellMed
    • Cosman Medical Inc.
    • CryoCor
    • Cryterion Medical, Inc.
    • Devoro Medical, Inc.
    • Ekos Corporation
    • EMcision, Ltd.
    • EndoTex Interventional Systems, Inc.
    • EndoChoice Holdings, Inc.
    • Enteric Medical Technologies, Inc.
    • Galil Medical, Inc.
    • Guidant Corporation
    • Intelect Medical, Inc.
    • IoGyn, Inc.
    • Labcoat Limited
    • Meadox Medicals, Inc.
    • Novate Medical Ltd.
    • nVision Medical Corporation
    • NxThera, Inc.
    • Pathworks Anatomic Pathology Laboratory
    • PneumRx Inc.
    • Precision Vascular Systems, Inc.
    • Protherics PLC
    • RadioTherapeutics Corporation
    • Revascular Therapeutics, Inc.
    • Roxwood Medical
    • Rubicon Medical Corporation
    • SCIMED, Inc.
    • Securus Medical Group, Inc.
    • Symetis SA
    • VENITI
    • Vessix Vascular, Inc.
    • Xlumena Inc.
UsernamePublicRestriction

Register